3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
95
Recurrence
11
Neoplasms, Plasma Cell
9
Immunoglobulin Light-chain Amyloidosis
6
Neoplasms
5
Smoldering Multiple Myeloma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Waldenstrom Macroglobulinemia
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Plasmacytoma
2
Neoplasm, Residual
2
Lymphoma
2
Leukemia, Plasma Cell
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Renal Insufficiency
1
Prostatic Neoplasms
1
Plasmablastic Lymphoma
1
Paraproteinemias
1
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
1
Myelodysplastic Syndromes
1
Microsatellite Unstable Colorectal Cancer
1
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Hypergammaglobulinemia
1
Disease
1
Chromosome 17 deletion
1
Interventions
varlilumab
1
daratumumab
1
belantamab mafodotin
1
Vincristine
1
Rituximab
1
Prednisone
1
Nivolumab
1
Immunoglobulin G
1
Etoposide
1
Doxorubicin
1
Disulfides
1
Dexamethasone
1
Cyclophosphamide
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Plasmablastic Lymphoma
×
daratumumab
×
Clear all
NCT04915248
2026-06-02
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2
Recruiting
28 enrolled